Evidence map›Paper›PMID 40107661›Full record

SynthesisEuropean respiratory review : an official journal of the European Respiratory Society2025

Risk factors for drug-resistant pathogens in community-acquired pneumonia: systematic review and meta-analysis.

Natsuki Nakagawa, Masahiro Katsurada, Yosuke Fukuda, Shingo Noguchi, Nobuyuki Horita, Makoto Miki, Hiroki Tsukada, Kazuyoshi Senda, Yuichiro Shindo, Hiroshi Mukae

Abstract readSystematic ReviewMeta-Analysis
In one paragraph

Synthesis in European respiratory review : an official journal of the European Respiratory Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Guideline-concordant therapy for community-onset pneumonia considering risk factors for drug-resistant pathogens: a propensity score-matched study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Observational
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Natsuki NakagawaDepartment of Respiratory Medicine, The University of Tokyo Hospital, Tokyo, Japan.ORCID https://orcid.org/0000-0001-8832-0807
Masahiro KatsuradaDepartment of Oncology Respiratory Medicine, Kita-Harima Medical Center, Ono City, Japan.
Yosuke FukudaDepartment of Medicine, Division of Respiratory Medicine, Yamanashi Red Cross Hospital, Minamitsuru-gun, Japan.
Shingo NoguchiDepartment of Respiratory Medicine, Tobata General Hospital, Kitakyushu-City, Japan.
Nobuyuki HoritaChemotherapy Center, Yokohama City University Hospital, Yokohama City, Japan.
Makoto MikiDepartment of Respiratory Medicine, Sendai Red Cross Hospital, Sendai City, Japan.
Hiroki TsukadaDepartment of Infection Control, Kashiwa Hospital of Tokyo Jikeikai Medical University, Kashiwa City, Japan.
Kazuyoshi SendaDepartment of Pharmaceutical Science, Kinjo Gakuin University, Nagoya City, Japan.
Yuichiro ShindoDepartment of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya City, Japan shindo.yuichiro.y7@f.mail.nagoya-u.ac.jp.
Hiroshi MukaeDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki City, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCommunity-acquired pneumonia (CAP) is a leading cause of death worldwide. Reducing inappropriate and excessive use of extended-spectrum antibiotics is essential for treating CAP effectively. Evaluating the risk of drug-resistant pathogens (DRPs) is crucial for determining initial antibiotic therapy in clinical settings.

methodsThis systematic review and meta-analysis assessed the risk factors for DRPs in patients with CAP. CAP-DRPs were defined as pathogens resistant to commonly used antibiotics for CAP, including nonpseudomonal β-lactams such as ceftriaxone or sulbactam-ampicillin, macrolides and respiratory fluoroquinolones. The studies included were divided into two cohorts, namely an all-patient cohort, comprising both culture-positive and culture-negative patients, and a culture-positive pneumonia cohort, comprising patients with identified causative pathogens. The primary objective of this study was to evaluate the risk factors for CAP-DRPs in the all-patient cohort.

results24 articles were included with 11 categorised into the all-patient cohort. The meta-analysis identified 11 significant risk factors for CAP-DRPs, namely prior DRP infection/colonisation, tracheostomy, severe respiratory failure requiring early induction of mechanical ventilation, prior use of antibiotics, chronic lung disease, COPD, wound care, neurological disorders, prior hospitalisation, nursing home residence and low activities of daily living.

conclusionTo our knowledge, this is the first systematic review focused on CAP-DRP. Unlike previous reviews, the all-patient and culture-positive pneumonia cohorts were analysed separately. Findings from the all-patient cohort are particularly relevant for guiding initial antimicrobial selection in clinical practice. Furthermore, the abovementioned factors should be considered when developing prediction models for CAP-DRPs.

Indexed as

Anti-Bacterial AgentsBacteriaCommunity-Acquired InfectionsDrug Resistance, BacterialPneumonia, BacterialAgedCommunity-Acquired PneumoniaFemaleHumansMaleMiddle AgedRisk AssessmentRisk FactorsTreatment OutcomeAnti-Bacterial Agents

Identifiers

PMID40107661
PMCPMC11920891

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.